Pneumococcal Vaccine Global Market Opportunities And Strategies To 2034

Description

Pneumococcal vaccines (PCV) are immunizations designed to protect against infections caused by Streptococcus pneumoniae, a bacterium responsible for illnesses such as pneumonia, meningitis, sinusitis, and bloodstream infections. The primary purpose of pneumococcal vaccine is to prevent serious and potentially life-threatening pneumococcal diseases, especially in high-risk groups like infants, older adults, and people with chronic illnesses.

The pneumococcal vaccine market consists of sales by entities (organizations, sole traders and partnerships) of pneumococcal vaccine that are deployed at scheduled intervals, with infant PCV doses at 2, 4, 6 and 12 months, with adult booster doses as recommended by bodies such as the Centers for Disease Control and Prevention (CDC), the US based national public health agency.

The global pneumococcal vaccine market was valued at $6,464.00 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 4.00%.

Increasing Prevalence Of Pneumococcal Contamination

During the historic period, the increasing prevalence of pneumococcal contamination supported the growth of the pneumococcal vaccine market. The rising incidence of pneumococcal infections, including pneumonia, meningitis and sepsis among vulnerable groups such as children and the elderly has intensified the need for preventive measures. Healthcare systems are increasingly prioritizing immunization to reduce hospital admissions and mortality. Untreated cases often result in costly hospital stays and long-term health complications, placing financial strain on both healthcare providers and insurers. Vaccination offers a cost-effective solution, leading governments and insurance providers to invest heavily in broader immunization efforts to reduce both clinical and economic burdens. For instance, in January 2022, according to the Center for Disease Control and Prevention, a US-based agency for public health, Pneumococcal pneumonia causes an estimated 150,000 hospitalizations per year in the United States, accounting for up to 30% of adult community-acquired pneumonia. Therefore, the increasing prevalence of pneumococcal contamination drove the growth of the pneumococcal vaccine market.

Innovative Pneumococcal Vaccine Enhances Pediatric Immunization By Targeting Local Disease Burden

Companies operating in the pneumococcal vaccine market are focusing on developing innovative formulations tailored to regional disease patterns and immune response optimization. These advancements aim to improve vaccine effectiveness, address local public health needs and reduce dependence on imported products. For example, in June 2025, CanSino Biologics Inc. (CanSinoBIO) is a China-based biopharmaceutical company launched its pneumococcal conjugate vaccine-iPneucia, a 13 valent formulation tailored to China's epidemiological needs. Designed with innovative dual carriers Cross-Reacting Material 197 (CRM197 + tetanus toxoid), it enhances immunogenicity while minimizing interference with other vaccines. Clinical data show strong antibody responses against key serotypes prevalent in Chinese children. As a domestically developed alternative to imported vaccines, iPneucia supports national immunization efforts, improves access and strengthens CanSinoBIO's position in the pediatric vaccine market.

The global pneumococcal vaccines market is highly concentrated, with large players operating in the market. The top 6 competitors in the market made up 100% of the total market in 2023.

Pneumococcal Vaccine Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global pneumococcal vaccine market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for pneumococcal vaccine? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The pneumococcal vaccine market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider pneumococcal vaccine market; and compares it with other markets.

The report covers the following chapters

Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by product type, by route of administration, by distribution channel and by end user.
Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by product type, by route of administration, by distribution channel and by end user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
Competitive Dashboard- Briefs on competitive dashboard of major players.
Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for pneumococcal vaccine providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

1) By Product Type: Pneumococcal Conjugate Vaccine (PCVs); Pneumococcal Polysaccharide Vaccine (PPV)
2) By Route Of Administration: Intramuscular; Subcutaneous
3) By Distribution Channel: Pharmacies; Community Clinics; Public Health Agencies; Other Distribution Channels
4) By End User: Pediatrics; Adults
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Serum Institute of India Pvt. Ltd.; Walvax Biotechnology Co. Ltd.
Countries: Australia; China; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; pneumococcal vaccine indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Product Code: o&s1767

1 Executive Summary

1.1 Pneumococcal Vaccine - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

6.1 General Market Definition
6.2 Summary
6.3 Pneumococcal Vaccine Market Definition And Segmentations
6.4 Market Segmentation By Product Type
- 6.4.1 Pneumococcal Conjugate Vaccine (PCVs)
- 6.4.2 Pneumococcal Polysaccharide Vaccine (PPV)
6.5 Market Segmentation By Route of Administration
- 6.5.1 Intramuscular
- 6.5.2 Subcutaneous
6.6 Market Segmentation By Distribution Channel
- 6.6.1 Pharmacies
- 6.6.2 Community Clinics
- 6.6.3 Public Health Agencies
- 6.6.4 Other Distribution Channels
6.7 Market Segmentation By End User
- 6.7.1 Pediatrics
- 6.7.2 Adults

7 Major Market Trends

7.1 Innovative Pneumococcal Vaccine Enhances Pediatric Immunization By Targeting Local Disease Burden
7.2 Innovative Conjugate Vaccines Aim To Bridge Global Immunization Gaps
7.3 Strategic Collaborations Accelerate Pneumococcal Vaccine Access
7.4 New Investment Wave Supports Scalable Pneumococcal Immunization
7.5 Advancing Adult Immunization Through Serotype-Specific Vaccines
7.6 Advances In Conjugate Vaccine Technology Improve Adult Immunity

8 Pneumococcal Vaccine Growth Analysis And Strategic Analysis Framework

8.1 Pneumococcal Vaccine PESTEL Analysis
- 8.1.1 Political
- 8.1.2 Economic
- 8.1.3 Social
- 8.1.4 Technological
- 8.1.5 Environmental
- 8.1.6 Legal
8.2 Analysis Of End User (B2B and B2C)
- 8.2.1 Pediatrics
- 8.2.2 Adults
8.3 Pneumococcal Vaccine Market Growth Rate Analysis
8.4 Global Historic Market Growth, 2019 - 2024, Value ($ Million)
- 8.4.1 Market Drivers 2019 - 2024
- 8.4.2 Market Restraints 2019 - 2024
8.5 Global Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
8.6 Forecast Growth Contributors/Factors
- 8.6.1 Quantitative Growth Contributors
- 8.6.2 Drivers
- 8.6.3 Restraints
8.7 Global Pneumococcal Vaccine Total Addressable Market (TAM)

9 Pneumococcal Vaccine Market Segmentation

9.1 Global Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.2 Global Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.3 Global Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.4 Global Pneumococcal Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.5 Global Pneumococcal Vaccine Market, Sub-Segmentation Of Pneumococcal Conjugate Vaccines (PCVs), By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.6 Global Pneumococcal Vaccine Market, Sub-Segmentation Of Pneumococcal Polysaccharide Vaccine (PPV), By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

10 Pneumococcal Vaccine Market, Regional and Country Analysis

10.1 Pneumococcal Vaccine Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
10.2 Pneumococcal Vaccine Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

11.1 Summary
11.2 Market Overview
- 11.2.1 Region Information
- 11.2.2 Market Information
- 11.2.3 Background Information
- 11.2.4 Government Initiatives
- 11.2.5 Regulations
- 11.2.6 Regulatory Bodies
- 11.2.7 Major Associations
- 11.2.8 Taxes Levied
- 11.2.9 Corporate Tax Structure
- 11.2.10 Investments
- 11.2.11 Major Companies
11.3 Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.4 Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.5 Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.6 Asia-Pacific Pneumococcal Vaccine Market: Country Analysis
11.7 China Market
11.8 Summary
11.9 Market Overview
- 11.9.1 Country Information
- 11.9.2 Market Information
- 11.9.3 Background Information
- 11.9.4 Government Initiatives
- 11.9.5 Regulations
- 11.9.6 Regulatory Bodies
- 11.9.7 Major Associations
- 11.9.8 Taxes Levied
- 11.9.9 Corporate Tax Structure
- 11.9.10 Investments
- 11.9.11 Major Companies
11.10 China Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.11 China Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.12 China Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.13 India Market
11.14 India Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.15 India Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.16 India Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.17 Japan Market
11.18 Summary
11.19 Market Overview
- 11.19.1 Country Information
- 11.19.2 Market Information
- 11.19.3 Background Information
- 11.19.4 Government Initiatives
- 11.19.5 Regulatory Bodies
- 11.19.6 Major Associations
- 11.19.7 Taxes Levied
- 11.19.8 Corporate Tax Structure
- 11.19.9 Investments
- 11.19.10 Major Companies
11.20 Japan Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.21 Japan Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.22 Japan Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.23 Australia Market
11.24 Australia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.25 Australia Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.26 Australia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.27 Indonesia Market
11.28 Indonesia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.29 Indonesia Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.30 Indonesia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.31 South Korea Market
11.32 Summary
11.33 Market Overview
- 11.33.1 Country Information
- 11.33.2 Market Information
- 11.33.3 Background Information
- 11.33.4 Government Initiatives
- 11.33.5 Regulations
- 11.33.6 Regulatory Bodies
- 11.33.7 Major Associations
- 11.33.8 Taxes Levied
- 11.33.9 Corporate Tax Structure
- 11.33.10 Investments
- 11.33.11 Major Companies
11.34 South Korea Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.35 South Korea Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.36 South Korea Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

12.1 Summary
12.2 Market Overview
- 12.2.1 Region Information
- 12.2.2 Market Information
- 12.2.3 Background Information
- 12.2.4 Government Initiatives
- 12.2.5 Regulations
- 12.2.6 Regulatory Bodies
- 12.2.7 Major Associations
- 12.2.8 Taxes Levied
- 12.2.9 Corporate tax structure
- 12.2.10 Investments
- 12.2.11 Major Companies
12.3 Western Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.4 Western Europe Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.5 Western Europe Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.6 Western Europe Pneumococcal Vaccine Market: Country Analysis
12.7 UK Market
12.8 UK Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.9 UK Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.10 UK Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.11 Germany Market
12.12 Germany Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.13 Germany Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.14 Germany Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.15 France Market
12.16 France Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.17 France Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.18 France Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.19 Italy Market
12.20 Italy Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.21 Italy Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.22 Italy Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.23 Spain Market
12.24 Spain Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.25 Spain Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.26 Spain Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

13.1 Summary
13.2 Market Overview
- 13.2.1 Region Information
- 13.2.2 Market Information
- 13.2.3 Background Information
- 13.2.4 Government Initiatives
- 13.2.5 Regulations
- 13.2.6 Regulatory Bodies
- 13.2.7 Major Associations
- 13.2.8 Taxes Levied
- 13.2.9 Corporate Tax Structure
- 13.2.10 Investments
- 13.2.11 Major Companies
13.3 Eastern Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.4 Eastern Europe Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.5 Eastern Europe Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.6 Eastern Europe Pneumococcal Vaccine Market: Country Analysis
13.7 Russia Market
13.8 Russia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.9 Russia Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.10 Russia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

14.1 Summary
14.2 Market Overview
- 14.2.1 Region Information
- 14.2.2 Market Information
- 14.2.3 Background Information
- 14.2.4 Government Initiatives
- 14.2.5 Regulations
- 14.2.6 Regulatory Bodies
- 14.2.7 Major Associations
- 14.2.8 Taxes Levied
- 14.2.9 Corporate Tax Structure
- 14.2.10 Investments
- 14.2.11 Major Companies
14.3 North America Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.4 North America Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.5 North America Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.6 North America Pneumococcal Vaccine Market: Country Analysis
14.7 USA Market
14.8 Summary
14.9 Market Overview
- 14.9.1 Country Information
- 14.9.2 Market Information
- 14.9.3 Background Information
- 14.9.4 Government Initiatives
- 14.9.5 Regulations
- 14.9.6 Regulatory Bodies
- 14.9.7 Major Associations
- 14.9.8 Taxes Levied
- 14.9.9 Corporate Tax Structure
- 14.9.10 Investments
- 14.9.11 Major Companies
14.10 USA Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.11 USA Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.12 USA Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.13 Canada Market
14.14 Summary
14.15 Market Overview
- 14.15.1 Country Information
- 14.15.2 Market Information
- 14.15.3 Background Information
- 14.15.4 Government Initiatives
- 14.15.5 Regulations
- 14.15.6 Regulatory Bodies
- 14.15.7 Major Associations
- 14.15.8 Taxes Levied
- 14.15.9 Corporate Tax Structure
- 14.15.10 Investments
- 14.15.11 Major Companies
14.16 Canada Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.17 Canada Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.18 Canada Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

15.1 Summary
15.2 Market Overview
- 15.2.1 Region Information
- 15.2.2 Market Information
- 15.2.3 Background Information
- 15.2.4 Government Initiatives
- 15.2.5 Regulations
- 15.2.6 Regulatory Bodies
- 15.2.7 Major Associations
- 15.2.8 Taxes Levied
- 15.2.9 Corporate Tax Structure
- 15.2.10 Investments
- 15.2.11 Major Companies
15.3 South America Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.4 South America Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.5 South America Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.6 South America Pneumococcal Vaccine Market: Country Analysis
15.7 Brazil Market
15.8 Brazil Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.9 Brazil Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.10 Brazil Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

16.1 Summary
16.2 Market Overview
- 16.2.1 Region Information
- 16.2.2 Market Information
- 16.2.3 Background Information
- 16.2.4 Government Initiatives
- 16.2.5 Regulations
- 16.2.6 Regulatory Bodies
- 16.2.7 Major Associations
- 16.2.8 Taxes Levied
- 16.2.9 Corporate Tax Structure
- 16.2.10 Investments
- 16.2.11 Major Companies
16.3 Middle East Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.4 Middle East Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.5 Middle East Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

17.1 Summary
17.2 Market Overview
- 17.2.1 Region Information
- 17.2.2 Market Information
- 17.2.3 Background Information
- 17.2.4 Government Initiatives
- 17.2.5 Regulations
- 17.2.6 Regulatory Bodies
- 17.2.7 Major Associations
- 17.2.8 Taxes Levied
- 17.2.9 Corporate Tax Structure
- 17.2.10 Investments
- 17.2.11 Major Companies
17.3 Africa Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.4 Africa Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.5 Africa Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape And Company Profiles

18.1 Company Profiles
18.2 Pfizer Inc
- 18.2.1 Company Overview
- 18.2.2 Products And Services
- 18.2.3 Business Strategy
- 18.2.4 Financial Overview
18.3 Merck & Co., Inc.
- 18.3.1 Company Overview
- 18.3.2 Products And Services
- 18.3.3 Business Strategy
- 18.3.4 Financial Overview
18.4 GlaxoSmithKline plc
- 18.4.1 Company Overview
- 18.4.2 Products And Services
- 18.4.3 Financial Overview
18.5 Serum Institute of India Pvt. Ltd
- 18.5.1 Company Overview
- 18.5.2 Products And Services
- 18.5.3 Business Strategy
- 18.5.4 Financial Overview
18.6 Walvax Biotechnology Co. Ltd
- 18.6.1 Company Overview
- 18.6.2 Products And Services
- 18.6.3 Financial Overview

19 Other Major And Innovative Companies

19.1 Biological E. Limited
- 19.1.1 Company Overview
- 19.1.2 Products And Services
19.2 Anhui Zhifei Longcom Biopharmaceutical Co. Ltd.
- 19.2.1 Company Overview
- 19.2.2 Products And Services
19.3 Shenzhen Kangtai Biological Products Co. Ltd. (Beijing Minhai Biotechnology Corporation Limited)
- 19.3.1 Company Overview
- 19.3.2 Products And Services
19.4 NPO Petrovax Pharm LLC
- 19.4.1 Company Overview
- 19.4.2 Products And Services
19.5 SK Bioscience Co. Ltd.
- 19.5.1 Company Overview
- 19.5.2 Products And Services
19.6 Vaxcyte, Inc.
- 19.6.1 Company Overview
- 19.6.2 Products And Services
19.7 Sinovac Biotech Ltd.
- 19.7.1 Company Overview
- 19.7.2 Products And Services
19.8 Astellas Pharma Inc.
- 19.8.1 Company Overview
- 19.8.2 Products And Services
19.9 LG Chem Ltd.
- 19.9.1 Company Overview
- 19.9.2 Products And Services
19.10 AIM Vaccine Co. Ltd.
- 19.10.1 Company Overview
- 19.10.2 Products And Services
19.11 Panacea Biotec Limited
- 19.11.1 Company Overview
- 19.11.2 Products And Services
19.12 China National Biotec Group (CNBG)
- 19.12.1 Company Overview
- 19.12.2 Products And Services
19.13 Inventprise LLC
- 19.13.1 Company Overview
- 19.13.2 Products And Services
19.14 Pnuvax Incorporated
- 19.14.1 Company Overview
- 19.14.2 Products And Services
19.15 Tergene Biotech Private Limited
- 19.15.1 Company Overview
- 19.15.2 Products And Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

22.1 SK bioscience Co. Ltd Acquired Fina Biosolutions
22.2 GSK Plc Acquired Affinivax

23 Recent Developments In The Pneumococcal Vaccine Market

23.1 New Pneumococcal Vaccine Launch Targets Nationwide Adult Protection
23.2 Next-Generation Pneumococcal Vaccine Approval Targets Drug-Resistant Strains

24 Opportunities And Strategies

24.1 Pneumococcal Vaccine Market In 2029 - Countries Offering Most New Opportunities
24.2 Pneumococcal Vaccine Market In 2029 - Segments Offering Most New Opportunities
24.3 Pneumococcal Vaccine Market In 2029 - Growth Strategies
- 24.3.1 Market Trend Based Strategies
- 24.3.2 Competitor Strategies

25 Pneumococcal Vaccine Market, Conclusions And Recommendations

25.1 Conclusions
25.2 Recommendations
- 25.2.1 Product
- 25.2.2 Place
- 25.2.3 Price
- 25.2.4 Promotion
- 25.2.5 People

26 Appendix

26.1 Geographies Covered
26.2 Market Data Sources
26.3 Research Methodology
26.4 Currencies
26.5 The Business Research Company
26.6 Copyright and Disclaimer